EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Detalhes bibliográficos
Autor(a) principal: Smolen, Josef S.
Data de Publicação: 2023
Outros Autores: Landewé, Robert B. M., Bergstra, Sytske Anne, Kerschbaumer, Andreas, Sepriano, Alexandre, Aletaha, Daniel, Caporali, Roberto, Edwards, Christopher John, Hyrich, Kimme L., Pope, Janet E., de Souza, Savia, Stamm, Tanja A., Takeuchi, Tsutomu, Verschueren, Patrick, Winthrop, Kevin L., Balsa, Alejandro, Bathon, Joan M., Buch, Maya H., Burmester, Gerd R., Buttgereit, Frank, Cardiel, Mario Humberto, Chatzidionysiou, Katerina, Codreanu, Catalin, Cutolo, Maurizio, den Broeder, Alfons A., El Aoufy, Khadija, Finckh, Axel, Fonseca, João Eurico, Gottenberg, Jacques-Eric, Haavardsholm, Espen A., Iagnocco, Annamaria, Lauper, Kim, Li, Zhanguo, McInnes, Iain B., Mysler, Eduardo F., Nash, Peter, Poor, Gyula, Ristic, Gorica G., Rivellese, Felice, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, Stoilov, Nikolay, Strangfeld, Anja, van der Helm-van Mil, Annette, van Duuren, Elsa, Vliet Vlieland, Theodora P. M., Westhovens, René, van der Heijde, Désirée
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10451/59913
Resumo: Copyright © 2022 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.
id RCAP_f17b095b3ad6094ec3401b797dadba70
oai_identifier_str oai:repositorio.ul.pt:10451/59913
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 updateAntirheumatic AgentsArthritisRheumatoidBiological TherapyCopyright © 2022 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.Objectives: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. Methods: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned to and participants finally voted on the level of agreement with each item. Results: The task force agreed on 5 overarching principles and 11 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); GCs; biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab including biosimilars), abatacept, rituximab, tocilizumab, sarilumab and targeted synthetic (ts) DMARDs, namely the Janus kinase inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib. Guidance on monotherapy, combination therapy, treatment strategies (treat-to-target) and tapering in sustained clinical remission is provided. Safety aspects, including risk of major cardiovascular events (MACEs) and malignancies, costs and sequencing of b/tsDMARDs were all considered. Initially, MTX plus GCs is recommended and on insufficient response to this therapy within 3-6 months, treatment should be based on stratification according to risk factors; With poor prognostic factors (presence of autoantibodies, high disease activity, early erosions or failure of two csDMARDs), any bDMARD should be added to the csDMARD; after careful consideration of risks of MACEs, malignancies and/or thromboembolic events tsDMARDs may also be considered in this phase. If the first bDMARD (or tsDMARD) fails, any other bDMARD (from another or the same class) or tsDMARD (considering risks) is recommended. With sustained remission, DMARDs may be tapered but should not be stopped. Levels of evidence and levels of agreement were high for most recommendations. Conclusions: These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost.This study was funded by European League Against Rheumatism.BMJ Publishing GroupRepositório da Universidade de LisboaSmolen, Josef S.Landewé, Robert B. M.Bergstra, Sytske AnneKerschbaumer, AndreasSepriano, AlexandreAletaha, DanielCaporali, RobertoEdwards, Christopher JohnHyrich, Kimme L.Pope, Janet E.de Souza, SaviaStamm, Tanja A.Takeuchi, TsutomuVerschueren, PatrickWinthrop, Kevin L.Balsa, AlejandroBathon, Joan M.Buch, Maya H.Burmester, Gerd R.Buttgereit, FrankCardiel, Mario HumbertoChatzidionysiou, KaterinaCodreanu, CatalinCutolo, Maurizioden Broeder, Alfons A.El Aoufy, KhadijaFinckh, AxelFonseca, João EuricoGottenberg, Jacques-EricHaavardsholm, Espen A.Iagnocco, AnnamariaLauper, KimLi, ZhanguoMcInnes, Iain B.Mysler, Eduardo F.Nash, PeterPoor, GyulaRistic, Gorica G.Rivellese, FeliceRubbert-Roth, AndreaSchulze-Koops, HendrikStoilov, NikolayStrangfeld, Anjavan der Helm-van Mil, Annettevan Duuren, ElsaVliet Vlieland, Theodora P. M.Westhovens, Renévan der Heijde, Désirée2023-10-20T13:51:27Z20232023-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/59913engAnn Rheum Dis. 2023 Jan;82(1):3-180003-496710.1136/ard-2022-2233561468-2060info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:09:12Zoai:repositorio.ul.pt:10451/59913Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:09:41.928335Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
title EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
spellingShingle EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Smolen, Josef S.
Antirheumatic Agents
Arthritis
Rheumatoid
Biological Therapy
title_short EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
title_full EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
title_fullStr EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
title_full_unstemmed EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
title_sort EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
author Smolen, Josef S.
author_facet Smolen, Josef S.
Landewé, Robert B. M.
Bergstra, Sytske Anne
Kerschbaumer, Andreas
Sepriano, Alexandre
Aletaha, Daniel
Caporali, Roberto
Edwards, Christopher John
Hyrich, Kimme L.
Pope, Janet E.
de Souza, Savia
Stamm, Tanja A.
Takeuchi, Tsutomu
Verschueren, Patrick
Winthrop, Kevin L.
Balsa, Alejandro
Bathon, Joan M.
Buch, Maya H.
Burmester, Gerd R.
Buttgereit, Frank
Cardiel, Mario Humberto
Chatzidionysiou, Katerina
Codreanu, Catalin
Cutolo, Maurizio
den Broeder, Alfons A.
El Aoufy, Khadija
Finckh, Axel
Fonseca, João Eurico
Gottenberg, Jacques-Eric
Haavardsholm, Espen A.
Iagnocco, Annamaria
Lauper, Kim
Li, Zhanguo
McInnes, Iain B.
Mysler, Eduardo F.
Nash, Peter
Poor, Gyula
Ristic, Gorica G.
Rivellese, Felice
Rubbert-Roth, Andrea
Schulze-Koops, Hendrik
Stoilov, Nikolay
Strangfeld, Anja
van der Helm-van Mil, Annette
van Duuren, Elsa
Vliet Vlieland, Theodora P. M.
Westhovens, René
van der Heijde, Désirée
author_role author
author2 Landewé, Robert B. M.
Bergstra, Sytske Anne
Kerschbaumer, Andreas
Sepriano, Alexandre
Aletaha, Daniel
Caporali, Roberto
Edwards, Christopher John
Hyrich, Kimme L.
Pope, Janet E.
de Souza, Savia
Stamm, Tanja A.
Takeuchi, Tsutomu
Verschueren, Patrick
Winthrop, Kevin L.
Balsa, Alejandro
Bathon, Joan M.
Buch, Maya H.
Burmester, Gerd R.
Buttgereit, Frank
Cardiel, Mario Humberto
Chatzidionysiou, Katerina
Codreanu, Catalin
Cutolo, Maurizio
den Broeder, Alfons A.
El Aoufy, Khadija
Finckh, Axel
Fonseca, João Eurico
Gottenberg, Jacques-Eric
Haavardsholm, Espen A.
Iagnocco, Annamaria
Lauper, Kim
Li, Zhanguo
McInnes, Iain B.
Mysler, Eduardo F.
Nash, Peter
Poor, Gyula
Ristic, Gorica G.
Rivellese, Felice
Rubbert-Roth, Andrea
Schulze-Koops, Hendrik
Stoilov, Nikolay
Strangfeld, Anja
van der Helm-van Mil, Annette
van Duuren, Elsa
Vliet Vlieland, Theodora P. M.
Westhovens, René
van der Heijde, Désirée
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório da Universidade de Lisboa
dc.contributor.author.fl_str_mv Smolen, Josef S.
Landewé, Robert B. M.
Bergstra, Sytske Anne
Kerschbaumer, Andreas
Sepriano, Alexandre
Aletaha, Daniel
Caporali, Roberto
Edwards, Christopher John
Hyrich, Kimme L.
Pope, Janet E.
de Souza, Savia
Stamm, Tanja A.
Takeuchi, Tsutomu
Verschueren, Patrick
Winthrop, Kevin L.
Balsa, Alejandro
Bathon, Joan M.
Buch, Maya H.
Burmester, Gerd R.
Buttgereit, Frank
Cardiel, Mario Humberto
Chatzidionysiou, Katerina
Codreanu, Catalin
Cutolo, Maurizio
den Broeder, Alfons A.
El Aoufy, Khadija
Finckh, Axel
Fonseca, João Eurico
Gottenberg, Jacques-Eric
Haavardsholm, Espen A.
Iagnocco, Annamaria
Lauper, Kim
Li, Zhanguo
McInnes, Iain B.
Mysler, Eduardo F.
Nash, Peter
Poor, Gyula
Ristic, Gorica G.
Rivellese, Felice
Rubbert-Roth, Andrea
Schulze-Koops, Hendrik
Stoilov, Nikolay
Strangfeld, Anja
van der Helm-van Mil, Annette
van Duuren, Elsa
Vliet Vlieland, Theodora P. M.
Westhovens, René
van der Heijde, Désirée
dc.subject.por.fl_str_mv Antirheumatic Agents
Arthritis
Rheumatoid
Biological Therapy
topic Antirheumatic Agents
Arthritis
Rheumatoid
Biological Therapy
description Copyright © 2022 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.
publishDate 2023
dc.date.none.fl_str_mv 2023-10-20T13:51:27Z
2023
2023-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10451/59913
url http://hdl.handle.net/10451/59913
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Ann Rheum Dis. 2023 Jan;82(1):3-18
0003-4967
10.1136/ard-2022-223356
1468-2060
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMJ Publishing Group
publisher.none.fl_str_mv BMJ Publishing Group
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799134651834433537